Moderna Stock More Than Doubled in a Month. Now Comes the Hard Part

Moderna, Inc‘s (NASDAQ:MRNA) biggest problem is no longer proving that its mRNA technology can work against cancer. Investors got that answer in August. The harder question now is whether one breakthrough melanoma result can become a commercially meaningful oncology franchise — and whether Moderna can deliver the manufacturing, regulatory and clinical follow-through needed to justify its dramatically higher valuation. Cancer Changed the Story Moderna shares have surged roughly 158% over the past month (or 2.6x), from around $62 in mid-August to around $160 on Sept. 16, after the company and Merck & Company, Inc (NYSE:MRK) announced a positive Phase 3 result for intismeran autogene, their personalized mRNA cancer therapy. The stock jumped nearly 177% on Aug. 19 alone after the trial met its primary recurrence-free-survival endpoint and a key secondary endpoint measuring distant metastasis-free survival. See More: Top Momentum Stocks The result was significant because it gave Moderna its first Phase 3 validation for an mRNA-based cancer therapy. The trial enrolled 1,137 patients with completely resected Stage IIB-IV melanoma, comparing the personalized vaccine plus Merck’s Keytruda with Keytruda alone. CEO Stéphane Bancel called the result an "extraordinary milestone" for Moderna and mRNA science. But investors are now paying for the possibility that this milestone becomes much bigger. The Next Proof Point Moderna and Merck plan to present detailed data at an upcoming medical meeting and engage regulators on potential filings. That makes the next catalyst less about another headline trial result and more about the evidence behind the topline announcement. The companies have also been studying intismeran across additional cancer settings. Moderna has previously highlighted its broader oncology pipeline, including multiple Phase 2 and Phase 3 programs. That expansion is crucial because a melanoma approval alone would not automatically transform Moderna’s earnings profile. The larger opportunity rests on whether the same personalized approach can work across multiple tumor types. The Commercial Challenge There is another hurdle that investors may be underestimating: manufacturing. Unlike a conventional mass-produced vaccine, a personalized cancer vaccine must be tailored to an individual patient’s tumor mutations. Commercializing personalized cancer vaccines will require manufacturers to solve a fundamentally different production challenge: making thousands of patient-specific batches in parallel while keeping turnaround times short. That makes Moderna’s next phase considerably different from the one that produced its COVID-19 success. The stock’s rally has already priced in a major change in expectations. The investment question now is whether Moderna can turn a breakthrough clinical result into repeatable approvals, scalable manufacturing and a broader oncology business. The upcoming detailed melanoma data and regulatory path will be the first tests of that thesis. Read Also: Merck and Moderna's Phase 3 Win Raises the Stakes for BioNTech and Roche Photo: pcruciatti / Shutterstock